Type 2 Diabetes (Metabolic Disorder) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits, and various other effects. Risk factors include family history, age, obesity, physical inactivity, and high blood pressure. This condition is handled by lifestyle alterations and regular medications.
The type 2 diabetes drugs in development market research report provides comprehensive information on the therapeutics under development for type 2 diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for type 2 diabetes and features dormant and discontinued projects.
What are the key targets in type 2 diabetes pipeline products market?
The key targets in the type 2 diabetes pipeline products market are glucagon like peptide 1 receptor, insulin receptor, dipeptidyl peptidase 4, adenosine monophosphate activated protein kinase, glucagon receptor, glucagon receptor, gastric inhibitory polypeptide receptor, glucokinase, peroxisome proliferator activated receptor gamma, and others.
Type 2 Diabetes Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
What are the key mechanisms of action in the type 2 diabetes pipeline products market?
The key mechanisms of action in the type 2 diabetes pipeline products market are glucagon like peptide 1 receptor agonist, insulin receptor agonist, dipeptidyl peptidase 4 inhibitor, sodium/glucose cotransporter 2 inhibitor, adenosine monophosphate activated protein kinase activator, glucagon receptor agonist, free fatty acid receptor 1 agonist, glucokinase activator, gastric inhibitory polypeptide receptor agonist, glucagon like peptide 1 activator, and others.
Type 2 Diabetes Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
What are the key routes of administration in the Type 2 diabetes pipeline products market?
The key routes of administration in the Type 2 diabetes pipeline products market are oral, subcutaneous, parenteral, intravenous, transdermal, buccal, inhalational, sublingual, intraarticular, intracardiac, and others.
Type 2 Diabetes Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
What are the different molecule types in the type 2 diabetes pipeline products market?
The different molecule types in the type 2 diabetes pipeline products market are small molecule, recombinant peptide, synthetic peptide, peptide, fusion protein, recombinant protein, biologic, monoclonal antibody, cell therapy, gene therapy, and others.
Type 2 diabetes Pipeline Products Market Analysis by Molecule Type
To know more about molecule types, download a free report sample
Which are the major companies in the type 2 diabetes pipeline products market?
The major companies in the type 2 diabetes pipeline products market are Eli Lilly and Co, Novo Nordisk AS, Merck & Co Inc, Tonghua Dongbao Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Sihuan Pharmaceutical Holdings Group Ltd, AstraZeneca Plc, Diasome Pharmaceuticals Inc, Intarcia Therapeutics Inc, and Thermalin Inc, Adocia SAS.
Type 2 Diabetes Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Scope
| Key targets | Glucagon Like Peptide 1 Receptor, Insulin Receptor, Dipeptidyl Peptidase 4, Adenosine Monophosphate Activated Protein Kinase, Glucagon Receptor, Glucagon Receptor, Gastric Inhibitory Polypeptide Receptor, Glucokinase, Peroxisome Proliferator Activated Receptor Gamma, and Others |
| Key mechanism of action | Glucagon Like Peptide 1 Receptor Agonist, Insulin Receptor Agonist, Dipeptidyl Peptidase 4 Inhibitor, Sodium/Glucose Cotransporter 2 Inhibitor, Adenosine Monophosphate Activated Protein Kinase Activator, Glucagon Receptor Agonist, Free Fatty Acid Receptor 1 Agonist, Glucokinase Activator, Gastric Inhibitory Polypeptide Receptor Agonist, Glucagon Like Peptide 1 Activator, and Others |
| Key routes of administration | Oral, Subcutaneous, Parenteral, Intravenous, Transdermal, Buccal, Inhalational, Sublingual, Intraarticular, Intracardiac, and Others |
| Molecule type | Small Molecule, Recombinant Peptide, Synthetic Peptide, Peptide, Fusion Protein, Recombinant Protein, Biologic, Monoclonal Antibody, Cell Therapy, Gene Therapy, and Others |
| Major companies | Eli Lilly and Co, Novo Nordisk AS, Merck & Co Inc, Tonghua Dongbao Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Sihuan Pharmaceutical Holdings Group Ltd, AstraZeneca Plc, Diasome Pharmaceuticals Inc, Intarcia Therapeutics Inc, and Thermalin Inc, Adocia SAS |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
GDPR + CCPA Compliant
Personal and transaction information are kept safe from unauthorised use.
Recently Viewed Reports
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.